In this episode of the podcast, the Oncology Brothers were joined by Dr. Tanios S. Bekaii-saab from Mayo Clinic to discuss the treatment landscape for hepatocellular carcinoma (HCC). The discussion focused on various aspects of HCC management, including early-stage treatment options such as liver transplant and local therapies like Y90, SBRT, or ablation.
For advanced or metastatic disease, the conversation delved into the use of Atezolizumab with Bevacizumab or dual checkpoint inhibitors based on the stride regimen. Dr. Tanios S. Bekaii-saab emphasized the importance of considering patient factors and performance status when choosing between treatment regimens.
The episode also touched on treatment options beyond the frontline and provided clinical pearls regarding the management of available TKIs. Overall, the discussion highlighted the complexity of HCC treatment decisions and the need for a multidisciplinary approach to patient care.
